Company Overview - Viking Therapeutics, Inc. (VKTX) closed at $27.05, reflecting a decrease of -1.92% from the previous trading session, underperforming compared to the S&P 500's loss of 0.64% [1] - Over the past month, shares of the company have declined by 15.32%, while the Medical sector gained 1.3% and the S&P 500 increased by 1.91% [1] Earnings Projections - The upcoming earnings release is highly anticipated, with projected EPS at -$0.68, indicating a significant drop of 209.09% compared to the same quarter last year [2] - Full-year Zacks Consensus Estimates forecast earnings of -$2.42 per share and revenue of $0 million, representing year-over-year changes of -139.6% and 0%, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics indicate the dynamic nature of near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for stocks [4] Zacks Rank Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with 1 stocks historically contributing an average annual return of +25% since 1988 [5] - Currently, Viking Therapeutics holds a Zacks Rank of 4 (Sell), with the Zacks Consensus EPS estimate remaining unchanged over the last 30 days [5] Industry Context - Viking Therapeutics operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

分组1 - Oculis Holding AG reported a quarterly loss of $0.59 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.53, and compared to a loss of $0.56 per share a year ago, indicating an earnings surprise of -11.32% [1] - The company posted revenues of $0.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.54%, and this represents an increase from year-ago revenues of $0.27 million [2] - Oculis Holding AG shares have increased by approximately 3.2% since the beginning of the year, while the S&P 500 has gained 8.7% [3] 分组2 - The earnings outlook for Oculis Holding AG is mixed, with the current consensus EPS estimate for the coming quarter at -$0.54 on revenues of $0.25 million, and for the current fiscal year at -$2.44 on revenues of $0.82 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 42% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adagene Inc. Sponsored ADR (ADAG) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Adagene Inc. Sponsored ADR is a member of the Medical sector. This group includes 974 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the averag ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Climb Bio, Inc. (CLYM) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Based on the most recent data, CLYM has returned 12.2% so far this year. Meanwhile, the Medical sector has returned an average of -2.9% on a year-to-date basis. This shows that Climb B ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Black Diamond (BDTX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Black Diamond is a member of the Medical sector. This group includes 976 individual stocks and currently holds a Zacks Sector Rank of #7. T ...

Company Overview - Armata Pharmaceuticals, Inc. (ARMP) is part of the Medical sector, which includes 978 individual stocks and currently holds a Zacks Sector Rank of 7 [2] - The company has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has increased by 24.7%, reflecting improved analyst sentiment [4] - Year-to-date, ARMP has returned approximately 36.8%, significantly outperforming the average return of -4.5% for Medical companies [4] Industry Context - Armata Pharmaceuticals operates within the Medical - Biomedical and Genetics industry, which consists of 488 stocks and currently ranks 97 in the Zacks Industry Rank [6] - The average return for stocks in this industry is 3% year-to-date, indicating that ARMP is performing better than its peers [6] Comparative Analysis - Another notable stock in the Medical sector is Avadel (AVDL), which has returned 28.5% year-to-date and has a Zacks Rank of 1 (Strong Buy) [5] - Avadel belongs to the Medical - Drugs industry, which has a current rank of 80 and has moved up by 8.3% year-to-date [6] Investment Outlook - Both Armata Pharmaceuticals and Avadel are highlighted as stocks that could continue their strong performance, making them of interest to investors in the Medical sector [7]

Group 1 - Alpha Cognition Inc. reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.46, and compared to a loss of $0.25 per share a year ago, indicating an earnings surprise of -41.30% [1] - The company posted revenues of $1.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.18%, compared to zero revenues a year ago [2] - Alpha Cognition Inc. shares have increased approximately 69.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 10% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Alpha Cognition Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.48 on revenues of $3.02 million, and for the current fiscal year, it is -$1.42 on revenues of $13.81 million [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, to which Alpha Cognition Inc. belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]

Fortress Biotech (FBIO) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.73 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -48.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.44 per share when it actually produced a loss of $0.48, delivering a surprise of -9.09%. Over the last four quarters, ...